Seattle, United States
Opticyte is a cutting-edge medical device startup based in the United States, founded in 2016. The company's slogan, "Preventing Organ Failure Through Early Detection," underlines its dedication to transforming the standard of care for organ failure, particularly in cases such as sepsis, where the current technology falls short in providing comprehensive diagnoses and treatment insights in real-time.
Opticyte's groundbreaking VitalO₂ monitor, unlike existing oximeters, provides accurate readings for individuals of all skin tones. This innovation has earned the company the FDA Breakthrough Device Designation, recognizing its potential to revolutionize patient care and save lives.
The company boasts a formidable executive and advisory team with expertise in optical spectroscopy, multivariate analysis technology, and medical device commercialization. Its early funding success, extensive research validation, and notable product development milestones have solidified Opticyte's position as a disruptive force in medical device innovation.
Notably, the company secured a Non Equity Assistance investment on June 6, 2023, with MedTech Innovator as the contributing investor. This financial support underscores the industry's confidence in Opticyte's potential to revolutionize organ failure prevention and treatment.
